MediWound to Report Third Quarter 2026 Financial Results

Conference Call and Webcast Scheduled for Thursday, November 12 th at 8:30 a.m. Eastern Time

YAVNE, Israel, October 29, 2026 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will release its financial results for the third quarter ended September 30, 2026, on Thursday, November 12, 2026.

Following the release, Mediwound’s management will host a conference call and live webcast at 8:30 a.m. Eastern Time to discuss the financial results and provide a corporate update.

Conference Call & Webcast Details

Toll-Free: 1-844-676-8833

Israel: 03-374-1008

International: 1-412-634-6869

Webcast: Click HERE

To access the call, participants should dial the applicable telephone number above at least 5 minutes prior to the start of the call. An archived version of the webcast will be available for replay on the Investors section of the MediWound website.

About MediWound

MediWound Ltd. (Nasdaq: MDWD) is a global leader in next-generation enzymatic therapeutics for tissue repair. The company’s FDA-approved biologic, NexoBrid ®, is indicated for the enzymatic removal of eschar in thermal burns and is marketed in the United States, the European Union, Japan, and additional international markets. MediWound’s late-stage development candidate, EscharEx ®, is an investigational therapy for the debridement of chronic wounds, with the potential to become a new standard of care in wound management.

For more information, visit www.mediwound.com and follow us on LinkedIn and X (formerly Twitter).

MediWound Contacts:

Hani Luxenburg Daniel Ferry

Chief Financial Officer Managing Director

MediWound Ltd. LifeSci Advisors, LLC

ir@mediwound.com daniel@lifesciadvisors.com